Every 8-K that Rapid Micro Biosystems, Inc. (RPID) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RPID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPID filings page.
Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier. Product revenue was $5.3 million and service revenue $2.8 million. Recurring revenue rose 14.3% to $5.0 million, representing 63% of total revenue, and consumable revenue grew more than 20% year over year. The company placed four new Growth Direct systems, completed nine validations and reached a milestone of 200 Growth Direct systems placed globally.
Total cost of revenue declined to $6.8 million, driving record second-quarter gross margin of 15.0%, up from 3.8% in the prior-year quarter. Operating expenses increased 8.9% to $13.5 million. Net loss was $12.9 million, or $0.27 per share, and non-GAAP adjusted EBITDA loss was $10.3 million. Cash, cash equivalents and short-term investments were approximately $20 million as of June 30, 2026. The company reaffirmed full year 2026 guidance for total revenue of $37.0–$41.0 million and gross margin of approximately 20%, and raised full year system validation guidance to at least 27.
Rapid Micro Biosystems, Inc. reported the results of its annual meeting of stockholders held on May 21, 2026. There were 41,267,511 Class A common shares eligible to vote, and 37,099,555 shares were represented in person or by proxy, establishing a quorum.
Stockholders elected Richard Kollender as a Class II director to serve until the 2029 annual meeting, with 23,180,585 votes for, 1,998,525 votes withheld, and 11,920,445 broker non-votes. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 37,096,030 votes for, 3,292 against, 233 abstentions, and no broker non-votes.
Rapid Micro Biosystems, Inc. entered an underwriting agreement for an underwritten offering of 3,581,000 Class A common shares with accompanying Series A and Series B common stock warrants, plus up to 1,463,000 pre-funded warrants with accompanying warrants. The company estimates net proceeds of about $8.9 million, to be used for working capital and general corporate purposes.
The warrants have exercise prices of $1.955 and $2.340 per share, with Series A warrants expiring one year after becoming exercisable and Series B warrants expiring five years after becoming exercisable. A concurrent registered direct offering with directors and officers covers 71,607 shares with matching warrant terms for approximately $140,000 in gross proceeds and is contingent on closing of the main offering.
Rapid Micro Biosystems reported first quarter 2026 revenue of $8.0 million, up 11.1% from $7.2 million a year earlier, driven by 36% growth in product revenue to $5.6 million and 27.7% growth in recurring revenue to $5.1 million. The company placed six new Growth Direct systems versus three in the prior-year quarter, but service revenue declined 21.9% to $2.4 million due to lower validation activity. Gross margin was 4.6% on cost of revenue of $7.6 million, while operating expenses rose 17.9% to $14.2 million, leading to a wider net loss of $14.3 million, or $0.31 per share, compared with a $11.3 million loss, or $0.26 per share, in 2025. Cash, cash equivalents, short-term investments, and restricted cash fell to $23.2 million at March 31, 2026, from $38.6 million at year-end 2025. The company reaffirmed full-year 2026 guidance for total revenue of $37.0 million to $41.0 million, gross margin of about 20%, and 30 to 38 Growth Direct system placements.
Rapid Micro Biosystems, Inc. announced that Chief Operating Officer John Wilson will depart effective April 10, 2026 to spend more time with his family, with no disagreement related to company operations or policies cited.
President and CEO Robert Spignesi will also serve as principal operating officer from that date, with no new material compensation arrangements. The company and Mr. Wilson entered into a Consulting Services and Separation Agreement on March 26, 2026, under which he will provide advisory services as a consultant at $200 per hour, up to 20 hours per month, through no later than June 30, 2026. The agreement extends the period to exercise his vested stock options through March 31, 2027 and places weekly limits on how many underlying Class A common shares he may dispose of, and includes customary release, confidentiality, cooperation and non‑disparagement terms.
Rapid Micro Biosystems reported record 2025 results with continued losses but improving scale. Total revenue reached $33.6 million in 2025, up 20% from 2024, with fourth quarter revenue of $11.3 million, a 37% increase year over year. Product revenue grew to $23.4 million for the year, while recurring revenue rose to $17.8 million.
Full-year gross margin improved to 3% from 0% in 2024, or 6% on a non-GAAP basis excluding a write-off of unusable inventory and related warranty expense. Net loss was $47.1 million, similar to $46.9 million in 2024, as operating expenses fell 3% to $48.4 million.
The company highlighted record multi-system orders from Amgen in late 2025 and a follow-on multi-system order from Samsung Biologics in early 2026, underscoring broader adoption of its Growth Direct platform. For 2026, it expects total revenue of $37.0 million to $41.0 million, 30 to 38 Growth Direct system placements and gross margin of approximately 20%.
Rapid Micro Biosystems, Inc. reported that it has released a press release with preliminary, unaudited revenue results and selected business highlights for the fourth quarter and full year ended December 31, 2025. The update is being shared through a furnished Form 8-K, which means the revenue information and commentary are provided for investors but are not deemed filed for liability purposes under certain Exchange Act provisions. The press release, attached as an exhibit, offers an early view of how the company’s business performed in late 2025 ahead of its formal financial statements.
Rapid Micro Biosystems (RPID) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. The filing also includes Exhibit 104 for the cover page inline XBRL.
Rapid Micro Biosystems secured a multi-tranche term loan facility of up to $45.0 million, drawing $20.0 million at closing. The facility is structured in four tranches with additional amounts available when commercial and operational milestones are met and includes a lender option tranche of $5.0 million. Loans are secured by a first-priority lien on substantially all assets of the company and may be guaranteed by subsidiaries.
Interest is floating with an initial rate of 11.5% per annum (floor 11.0%), a 36-month interest-only period followed by amortization, and a maturity date of September 1, 2030. Fees include a 1.0% commitment fee on amounts drawn, prepayment premiums (3.0% year one, 2.0 year two, 1.0% thereafter), and a 4.0% end-of-term payment on amounts drawn. Each draw requires issuance of warrants equal to 3.0% of the drawn amount (cashless exercise, ten-year term); the company issued warrants for up to 179,104 shares at a $3.35 exercise price for the first tranche. The agreement contains customary covenants and defaults but does not require maintaining specific revenue or cash thresholds.